tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Skin Diseases, Papulosquamous D017444 2 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Venous Insufficiency D014689 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Telangiectasis D013684 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Paronychia D010304 3 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Facial Neoplasms D005153 3 associated lipids
Gingivitis D005891 3 associated lipids
Hemophilia B D002836 3 associated lipids
Pouchitis D019449 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schmidt KJ et al. Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - authors' reply. 2013 Aliment. Pharmacol. Ther. pmid:23336691
Baumgart DC et al. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. 2003 Aliment. Pharmacol. Ther. pmid:12755840
Yamamoto T et al. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. 2016 Aliment. Pharmacol. Ther. pmid:26762838
Travis S Review article: saving the colon in severe colitis - the case for medical therapy. 2006 Aliment. Pharmacol. Ther. pmid:16961749
Romano C et al. Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis. 2010 Aliment. Pharmacol. Ther. pmid:20148798
McSharry K et al. Systematic review: the role of tacrolimus in the management of Crohn's disease. 2011 Aliment. Pharmacol. Ther. pmid:21999607
Itoh S et al. Inhibition of CN (protein phosphatase-2B) suppresses Ca2+-mediated acid secretion in rats. 2002 Aliment. Pharmacol. Ther. pmid:11966520
Beckebaum S et al. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. 2009 Aliment. Pharmacol. Ther. pmid:19624550
Firpi RJ et al. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. 2004 Aliment. Pharmacol. Ther. pmid:15113371
Högenauer C et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. 2003 Aliment. Pharmacol. Ther. pmid:12940927
Trotter JF et al. Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients. 2005 Aliment. Pharmacol. Ther. pmid:15963078
Yamamoto T et al. Letter: which patient profile for tacrolimus in ulcerative colitis? Authors' reply. 2016 Aliment. Pharmacol. Ther. pmid:27137731
Laharie D and Poullenot F Letter: which patient profile for tacrolimus in ulcerative colitis? 2016 Aliment. Pharmacol. Ther. pmid:27137730
Lawrance IC and Copeland TS Rectal tacrolimus in the treatment of resistant ulcerative proctitis. 2008 Aliment. Pharmacol. Ther. pmid:18761706
Liberal R et al. Expert clinical management of autoimmune hepatitis in the real world. 2017 Aliment. Pharmacol. Ther. pmid:28004405
Segal JP et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. 2017 Aliment. Pharmacol. Ther. pmid:28008631
Yamamoto T et al. Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply. 2016 Aliment. Pharmacol. Ther. pmid:27040167
Taylor KM and Sparrow MP Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis. 2016 Aliment. Pharmacol. Ther. pmid:27040166
Haagsma EB et al. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. 2003 Aliment. Pharmacol. Ther. pmid:12848624
Nakase H et al. Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus. 2010 Aliment. Pharmacol. Ther. pmid:20636704